Company
Tandem Diabetes Care
Last checked: Nov 21, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
25
510(k), De Novo and PMA
Device trials
17
As lead sponsor, any status
Adverse event reports
239,871
Received Nov 1, 2025 to Nov 21, 2026
Recall records
15
One per recalled product
Tandem Diabetes Care is on our public-company list (ticker TNDM). Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
TNDM
Nasdaq · TANDEM DIABETES CARE INC
Public float
$1.30B
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$1.01B
Fiscal year ending Dec 31, 2025
Net income
-$205M
Fiscal year ending Dec 31, 2025
R&D spending
$193M
Fiscal year ending Dec 31, 2025
Cash
$72.8M
As of Sep 30, 2026
Long-term debt
$603M
As of Sep 30, 2026
Shares outstanding
69.8M
As of Nov 2, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2024 | – | -$6.7M | – | $307M |
| 2023 | – | $4.2M | – | – |
| 2022 | – | $17.5M | – | – |
| 2021 | – | $51.3M | – | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Aug 30, 2012 | Equity | $36.4M | $50.0M | 43 | Rule 506 | Form D ↗Sep 11, 2012 |
2 more funding rounds with a free account
Company details
From the company's latest Form D.
- Legal name
- TANDEM DIABETES CARE INC
- Headquarters
- San Diego, California
- Incorporated
- Delaware in 2008
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Technology
- SEC filer
- CIK 1438133 ↗
Executives, directors and promoters
As listed on the latest Form D.
9 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors from funding announcements and the firms' own portfolio pages.
The investor database is free with an account
Sign up free with your name, company and ZIP code to see the 5%+ shareholders and government grant funders behind device companies.
Latest FDA decisions
The 8 newest of 25 since 2015.
- Control-IQ+ technology510(k)
K260429 · Decided Apr 24, 2026 · 73 days after receipt
Device type: Interoperable Automated Glycemic Controller (QJI) · Laboratory Medicine & Pathology
24 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in FranceRecruiting
NCT07211126 · 350 participants (planned) · Start Mar 3, 2026 · Primary completion Dec 2027
Device: t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) · For: Diabetes Mellitus, Type 1
Sites: Agen, France; Angers, France; Bron, France · 25 sites in all
16 more trials with a free account
Reports received
239,871
Received Nov 1, 2025 to Nov 21, 2026. Includes 3 of another or unstated type.
Malfunction reports
213,872
89% of reports
Injury reports
25,956
11% of reports
Death reports
40
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 14,074 | 1,347 | 0 | 0 |
| Jan 24 | 14,795 | 1,536 | 1 | 0 |
| Feb 24 | 13,092 | 1,521 | 1 | 1 |
| Mar 24 | 17,493 | 1,796 | 1 | 0 |
| Apr 24 | 17,984 | 2,141 | 6 | 0 |
| May 24 | 17,654 | 2,184 | 1 | 0 |
| Jun 24 | 15,015 | 1,828 | 0 | 0 |
| Jul 24 | 22,880 | 2,686 | 2 | 0 |
| Aug 24 | 22,619 | 2,518 | 4 | 0 |
| Sep 24 | 18,332 | 1,874 | 4 | 0 |
| Oct 24 | 19,767 | 2,242 | 7 | 0 |
| Nov 24 | 15,115 | 1,660 | 2 | 0 |
| Dec 24 | 18,708 | 2,046 | 1 | 0 |
| Jan 25 | 22,351 | 2,061 | 2 | 0 |
| Feb 25 | 14,936 | 1,591 | 3 | 0 |
| Mar 25 | 16,981 | 1,879 | 3 | 0 |
| Apr 25 | 18,189 | 2,058 | 3 | 0 |
| May 25 | 17,517 | 2,280 | 4 | 0 |
| Jun 25 | 14,625 | 2,378 | 2 | 0 |
| Jul 25 | 24,335 | 3,274 | 3 | 0 |
| Aug 25 | 20,114 | 2,631 | 5 | 0 |
| Sep 25 | 19,225 | 2,860 | 0 | 0 |
| Oct 25 | 19,550 | 2,718 | 2 | 0 |
| Nov 25 | 16,398 | 2,142 | 2 | 0 |
| Dec 25 | 21,045 | 2,387 | 5 | 1 |
| Jan 26 | 17,617 | 2,125 | 5 | 0 |
| Feb 26 | 16,991 | 1,921 | 2 | 0 |
| Mar 26 | 18,418 | 2,336 | 1 | 0 |
| Apr 26 | 17,515 | 2,210 | 6 | 0 |
| May 26 | 16,564 | 2,096 | 1 | 0 |
| Jun 26 | 17,731 | 2,298 | 4 | 0 |
| Jul 26 | 18,816 | 2,038 | 1 | 1 |
| Aug 26 | 17,464 | 2,152 | 6 | 1 |
| Sep 26 | 17,697 | 2,139 | 5 | 0 |
| Oct 26 | 17,616 | 2,112 | 2 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
2 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0316-2027 · Started Sep 23, 2026 · Posted by FDA Oct 30, 2026
Reason given: Tandem Diabetes Care, Inc. ( Tandem ) has identified that certain Tandem Mobi insulin pumps may generate false-positive occlusion alarms when no actual insulin flow obstruction is present. Investigation determined that increased friction within the drive module can reduce available motor power and, under certain...
Cause as FDA categorized it: Process change control · Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG)
14 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.